If you are considering psychedelic-assisted treatment in Romania (for yourself or for someone close to you), there is exactly one funded route in July 2026, and it runs through a single publicly documented door: the national subprogram for major depressive disorder at Bucharest's Obregia psychiatric hospital. This guide covers how that subprogram works, who qualifies, how to submit a dossier, and what has no legal path here; you can begin orienting yourself with our eligibility check.
TL;DR Esketamine (Spravato) is paid for by the national insurer CNAS through a dedicated subprogram for major depressive disorder created by HG 423/2022, implemented at the Obregia hospital in Bucharest. Enrolment is by dossier: you email your medical file and a signed consent form, and hospital psychiatrists check it against the therapeutic protocol, adults, moderate-to-severe episode, at least two failed antidepressants, esketamine combined with an SSRI or SNRI. The subprogram is a workaround for the standard reimbursement list, which esketamine failed to reach in the 2020 assessment. Ketamine-assisted therapy has no publicly documented programme, and psilocybin and MDMA are research-only.
At a glance
| Route | Substance | Status in Romania | Who qualifies | Cost |
|---|---|---|---|---|
| National subprogram | Esketamine (Spravato) | Running; funded by CNAS under HG 423/2022; documented at Obregia hospital, Bucharest | Adults with treatment-resistant depression after at least two failed antidepressants in the current moderate-to-severe episode; SSRI/SNRI co-treatment | Covered by the subprogram |
| Standard pharmacy reimbursement | Esketamine | Not available: the 2020 HTA scored it below the inclusion threshold | – | Self-pay outside the subprogram |
| Ketamine-assisted therapy | Ketamine (off-label) | No publicly documented programme | – | – |
| Psilocybin / MDMA therapy | Psilocybin, MDMA | Research only; no legal route | – | – |
| Clinical trials | Various | Check the registries; availability varies | Study-specific criteria | Free |
How Romania ended up with a subprogram instead of a list entry
The story explains the route. In 2020 the national medicines agency ANM assessed esketamine for treatment-resistant depression and gave it 42 points (below the threshold for the reimbursement list) concluding that the drug "does not meet the conditions for inclusion" in the list of medicines covered by the health insurance system (ANM HTA report 19271/2020). The report leaned on the fact that NICE in England had at that point declined to recommend Spravato for reimbursement.
Access came by another door. Government decision HG 423/2022 on national health programmes created a Subprogramul Național de Tratament al bolnavilor cu tulburare depresivă majoră (a national treatment subprogram for major depressive disorder) reimbursed by the national insurance house CNAS, and a therapeutic protocol for esketamine (code N06AX27) was approved by Order MS/CNAS 1837/447/2023 (protocol list, pages 183–184). The result is a hospital-run programme with its own budget rather than a pharmacy benefit.
The subprogram at Obregia: who qualifies and how to apply
The Obregia clinical psychiatry hospital in Bucharest, the country's largest, runs the subprogram and documents it publicly (spital-obregia.ro). Spravato is indicated in combination with an SSRI (sertraline, citalopram, escitalopram, paroxetine, fluoxetine, fluvoxamine) or an SNRI (venlafaxine, duloxetine) for adults with treatment-resistant major depressive disorder who have not responded to at least two different antidepressant treatments in the current moderate-to-severe episode.
How to apply: Enrolment is decided after a review of your medical documents against the therapeutic protocol. The dossier can be submitted electronically to pns.esketamina@spital-obregia.ro and consists of two things: a signed personal-data consent declaration (downloadable from the hospital page) and your medical file. The hospital lists direct phone numbers for each adult psychiatry section for questions from patients, families and referring doctors. The practical currency is the same as everywhere: a written treatment history (drugs, doses, durations, outcomes) assembled before you write the email.
Cost: for enrolled patients the treatment is covered by CNAS through the subprogram. Outside it, esketamine is not on the standard reimbursement list, which means self-pay, and no Romanian price list for self-pay esketamine is published.
What we don't know: Whether hospitals other than Obregia currently deliver the subprogram is not publicly documented; the programme is national on paper, but Obregia is the only site that publishes enrolment instructions. No data exists in public on patient volumes, budget ceilings or waiting times, and none of the authorities publish a centre list. If you are outside Bucharest, the dossier-by-email mechanism is still the documented starting point.
Ketamine, psilocybin and MDMA: no public route
Off-label ketamine for depression has no publicly documented clinic programme in Romania: nothing comparable to the private ketamine clinics of Western Europe advertises openly, and we list none. Psilocybin and MDMA remain controlled substances with no medical-access or compassionate-use route. Anyone selling psychedelic "therapy" in Romania today is operating outside the law. If a regulated psychedelic-therapy framework matters to you, the nearest one being built is Czech medical psilocybin; see our Czechia guide.
Clinical trials
Romania hosts industry psychiatric trials regularly, but no recruiting psychedelic or esketamine trial in Romania was listed at the time of writing; check ClinicalTrials.gov and the EU CTIS registry for current listings, and browse trial sites in Romania. Our trials guide explains how phases, placebo arms and consent work. To see who is listed near you, browse providers in Romania.
What to expect in treatment
Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026: this section and the risks section below.
These routes share a shape (medical screening, supervised administration, structured follow-up), but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common (though they do not occur in everyone), and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.
A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists, and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few; dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
- A personal or family history of psychosis or bipolar disorder: a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use: any of these may make treatment inappropriate or require specialist assessment.
A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign; see our clinic-choice guide. To see who is listed near you, browse providers in Romania.
Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.
— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess medical reviewers
Frequently asked questions
Is Spravato reimbursed in Romania?
Not through the pharmacy list: through a national subprogram. If you are enrolled at an implementing hospital, CNAS covers the treatment under HG 423/2022; if you are not enrolled, there is no reimbursement.
How long does dossier review take?
The hospital does not publish timelines. What you control is the quality of the file: documented proof of two adequate failed antidepressant trials in the current episode does most of the work. Call the section phone numbers listed on Obregia's page if you hear nothing.
Can I enrol if I live outside Bucharest?
The dossier is submitted by email, so distance is no barrier to applying. Treatment itself requires supervised administration at the implementing hospital, so plan for travel to Bucharest unless your regional hospital confirms it participates.
Is ketamine therapy available privately in Romania?
We found no publicly documented programme. Treat any offer with caution, ask exactly who prescribes and supervises, and see our clinic-choice guide before paying anyone.
Coming from another country? Whether a clinic will take a non-resident self-pay patient, what a Spravato induction schedule means for a visitor, and where cross-border treatment actually works: ketamine & psychedelic therapy in Europe for international patients.
Sources
- Spitalul Obregia: Subprogramul Național de Tratament al bolnavilor cu tulburare depresivă majoră — enrolment instructions
- Obregia hospital: Therapeutic protocol for esketamine (PDF)
- CNAS: List of therapeutic protocols approved by Order MS/CNAS 1837/447/2023 — code N06AX27, pages 183–184
- ANM: HTA report 19271/2020 on Esketaminum (Spravato) — 42 points, conditions for list inclusion not met
- ANMDMR: Spravato (esketamina) — educational materials and safety information
- Legislative portal: Application norms for the national health programmes (30 March 2022, under HG 423/2022)
- EMA: Spravato (esketamine) EPAR
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Subprogram rules and protocols change; always verify current requirements with CNAS, the implementing hospital, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.